Cell therapy · developed by Vericel
Tissue Repair Cells (ixmyelocel-t) are an autologous bone marrow tissue graft, processed from the patient's own aspirated bone marrow and absorbed onto a gelfoam carrier. They are studied for alveolar bone loss, with the cells placed in the tooth extraction socket.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00755911 | Phase 1/2 | Alveolar Bone Loss | Completed | VCEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alveolar Bone Loss
Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.
See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VCEL catalysts and pipeline →